An approach to insulin tapering and discontinuation after glucagon-like peptide-1 receptor agonist initiation

被引：0
作者：
Crossey, Caroline D. [1 ]
Garcia, Andrew [2 ]
Berenbrok, Lucas A. [3 ]
机构：
[1] UPMC Shadyside Family Hlth Ctr, Pittsburgh, PA 15232 USA
[2] UPMC Shadyside Hosp, Pittsburgh, PA USA
[3] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA
来源：
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2022年 / 79卷 / 22期
关键词：
diabetes; GLP1; agonists; insulin; primary care; SGLT2; inhibitors;
D O I：
10.1093/ajhp/zxac230
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1978 / 1979
页数：2
相关论文
共 9 条
[1]   1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes-2022 [J].
American Diabetes Association Professional Practice Committee .
DIABETES CARE, 2022, 45 :S8-S16
[2]   Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data [J].
Chudleigh, Richard A. ;
Platts, Julia ;
Bain, Stephen C. .
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2020, 13 :433-438
[3]   Real-world evaluation of insulin requirements after GLP1 agonist or SGLT2 inhibitor initiation and titration [J].
George, Jamie ;
Lobkovich, Alison ;
Nardolillo, Joseph ;
Farhat, Nada ;
Kolander, Sarah ;
Thomas, Emily .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (14) :1151-1157
[4]   Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial [J].
Gerstein, Hertzel C. ;
Colhoun, Helen M. ;
Dagenais, Gilles R. ;
Diaz, Rafael ;
Lakshmanan, Mark ;
Pais, Prem ;
Probstfield, Jeffrey ;
Riesmeyer, Jeffrey S. ;
Riddle, Matthew C. ;
Ryden, Lars ;
Xavier, Denis ;
Atisso, Charles Messan ;
Dyal, Leanne ;
Hall, Stephanie ;
Rao-Melacini, Purnima ;
Wong, Gloria ;
Avezum, Alvaro ;
Basile, Jan ;
Chung, Namsik ;
Conget, Ignacio ;
Cushman, William C. ;
Franek, Edward ;
Hancu, Nicolae ;
Hanefeld, Markolf ;
Holt, Shaun ;
Jansky, Petr ;
Keltai, Matyas ;
Lanas, Fernando ;
Leiter, Lawrence A. ;
Lopez-Jaramillo, Patricio ;
Cardona Munoz, Ernesto German ;
Pirags, Valdis ;
Pogosova, Nana ;
Raubenheimer, Peter J. ;
Shaw, Jonathan E. ;
Sheu, Wayne H-H ;
Temelkova-Kurktschiev, Theodora .
LANCET, 2019, 394 (10193) :121-130
[5]   Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes [J].
Hauber, A. Brett ;
Han, Steven ;
Yang, Jui-Chen ;
Gantz, Ira ;
Tunceli, Kaan ;
Gonzalez, Juan Marcos ;
Brodovicz, Kimberly ;
Alexander, Charles M. ;
Davies, Michael ;
Iglay, Kristy ;
Zhang, Qiaoyi ;
Radican, Larry .
PATIENT PREFERENCE AND ADHERENCE, 2013, 7 :937-949
[6]  
Jar'arah D., 2021, CLIN MED INSIGHTS EN, V14
[7]   Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes [J].
Marso, Steven P. ;
Daniels, Gilbert H. ;
Brown-Frandsen, Kirstine ;
Kristensen, Peter ;
Mann, Johannes F. E. ;
Nauck, Michael A. ;
Nissen, Steven E. ;
Pocock, Stuart ;
Poulter, Neil R. ;
Ravn, Lasse S. ;
Steinberg, William M. ;
Stockner, Mette ;
Zinman, Bernard ;
Bergenstal, Richard M. ;
Buse, John B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04) :311-322
[8]   Pharmacist roles in the management of patients with type 2 diabetes [J].
Sisson, Evan ;
Kuhn, Catherine .
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2009, 49 :S41-S45
[9]   Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review [J].
Yang, Chen-Yi ;
Chen, Ying-Ren ;
Ou, Huang-Tz ;
Kuo, Shihchen .
CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
1